Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.31)
# 488
Out of 4,412 analysts
111
Total ratings
37.14%
Success rate
31.22%
Average return
Main Sectors:
Top Industries:
34 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABEO Abeona Therapeutics | Reiterates: Overweight | $36 | $3.26 | +1,004.29% | 5 | Apr 23, 2024 | |
| TSHA Taysha Gene Therapies | Reiterates: Overweight | $7 | $2.39 | +192.89% | 9 | Apr 19, 2024 | |
| PTCT PTC Therapeutics | Reiterates: Overweight | $45 | $28.57 | +57.51% | 10 | Apr 12, 2024 | |
| ETNB 89bio | Reiterates: Overweight | $29 | $8.26 | +251.09% | 7 | Apr 5, 2024 | |
| RARE Ultragenyx Pharmaceutical | Reiterates: Overweight | $107 | $44.24 | +141.86% | 6 | Apr 5, 2024 | |
| HUMA Humacyte | Reiterates: Overweight | $7 | $3.99 | +75.44% | 5 | Apr 1, 2024 | |
| ATNM Actinium Pharmaceuticals | Reiterates: Overweight | $21 | $6.87 | +205.68% | 2 | Apr 1, 2024 | |
| MREO Mereo BioPharma Group | Reiterates: Overweight | $7 | $2.74 | +155.47% | 4 | Mar 28, 2024 | |
| CLDX Celldex Therapeutics | Reiterates: Overweight | $67 | $36.30 | +84.57% | 7 | Mar 22, 2024 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $2 → $3 | $1.10 | +172.73% | 2 | Mar 6, 2024 | |
| ADMA ADMA Biologics | Maintains: Overweight | $6.5 → $8 | $6.55 | +22.14% | 4 | Feb 29, 2024 | |
| FOLD Amicus Therapeutics | Reiterates: Overweight | $22 | $10.28 | +114.01% | 4 | Feb 29, 2024 | |
| SRPT Sarepta Therapeutics | Reiterates: Neutral | $128 | $128.77 | -0.60% | 8 | Feb 29, 2024 | |
| LCTX Lineage Cell Therapeutics | Reiterates: Overweight | $6 | $1.14 | +426.32% | 3 | Feb 5, 2024 | |
| CAPR Capricor Therapeutics | Initiates: Overweight | $8 | $5.41 | +47.87% | 1 | Jan 5, 2024 | |
| QURE uniQure | Reiterates: Overweight | $21 | $4.53 | +363.58% | 2 | Dec 20, 2023 | |
| IRON Disc Medicine | Reiterates: Overweight | $85 | $27.55 | +208.53% | 3 | Dec 20, 2023 | |
| SLNO Soleno Therapeutics | Maintains: Overweight | $19 → $35 | $37.89 | -7.63% | 3 | Sep 26, 2023 | |
| OTLK Outlook Therapeutics | Downgrades: Neutral | $90 → $20 | $8.43 | +137.25% | 2 | Aug 30, 2023 | |
| DRTS Alpha Tau Medical | Reiterates: Overweight | $23 | $2.41 | +856.34% | 2 | Aug 29, 2023 | |
| MBIO Mustang Bio | Reiterates: Overweight | $18 | $0.32 | +5,594.40% | 1 | Aug 24, 2023 | |
| OCUP Ocuphire Pharma | Reiterates: Overweight | $17 | $1.61 | +955.90% | 3 | Aug 14, 2023 | |
| DRRX DURECT | Maintains: Overweight | $44 → $41 | $0.93 | +4,302.45% | 2 | Aug 10, 2023 | |
| XFOR X4 Pharmaceuticals | Maintains: Overweight | $3 | $1.17 | +157.51% | 2 | Mar 22, 2023 | |
| GLTO Galecto | Initiates: Overweight | $16 | $0.70 | +2,170.15% | 1 | Mar 17, 2023 | |
| IBIO iBio, Inc. | Downgrades: Neutral | $1,250 → $85 | $1.76 | +4,729.55% | 3 | Oct 7, 2022 | |
| HEPA Hepion Pharmaceuticals | Initiates: Overweight | $70 | $1.37 | +5,009.49% | 1 | Feb 28, 2022 | |
| EVLO Evelo Biosciences | Initiates: Overweight | n/a | $0.05 | - | 1 | Jun 23, 2021 | |
| CMMB Chemomab Therapeutics | Initiates: Overweight | n/a | $0.64 | - | 1 | May 26, 2021 | |
| OCGN Ocugen | Downgrades: Neutral | n/a | $1.28 | - | 3 | May 7, 2021 | |
| MRKR Marker Therapeutics | Initiates: Overweight | n/a | $4.29 | - | 1 | Mar 19, 2021 | |
| EVGN Evogene | Initiates: Overweight | n/a | $0.63 | - | 1 | Dec 1, 2020 | |
| GLMD Galmed Pharmaceuticals | Assumes: Overweight | n/a | $0.39 | - | 1 | Jan 30, 2020 | |
| PHGE BiomX | Initiates: Overweight | n/a | $0.35 | - | 1 | Jan 9, 2020 |
Abeona Therapeutics
Apr 23, 2024
Reiterates: Overweight
Price Target: $36
Current: $3.26
Upside: +1,004.29%
Taysha Gene Therapies
Apr 19, 2024
Reiterates: Overweight
Price Target: $7
Current: $2.39
Upside: +192.89%
PTC Therapeutics
Apr 12, 2024
Reiterates: Overweight
Price Target: $45
Current: $28.57
Upside: +57.51%
89bio
Apr 5, 2024
Reiterates: Overweight
Price Target: $29
Current: $8.26
Upside: +251.09%
Ultragenyx Pharmaceutical
Apr 5, 2024
Reiterates: Overweight
Price Target: $107
Current: $44.24
Upside: +141.86%
Humacyte
Apr 1, 2024
Reiterates: Overweight
Price Target: $7
Current: $3.99
Upside: +75.44%
Actinium Pharmaceuticals
Apr 1, 2024
Reiterates: Overweight
Price Target: $21
Current: $6.87
Upside: +205.68%
Mereo BioPharma Group
Mar 28, 2024
Reiterates: Overweight
Price Target: $7
Current: $2.74
Upside: +155.47%
Celldex Therapeutics
Mar 22, 2024
Reiterates: Overweight
Price Target: $67
Current: $36.30
Upside: +84.57%
Rigel Pharmaceuticals
Mar 6, 2024
Maintains: Neutral
Price Target: $2 → $3
Current: $1.10
Upside: +172.73%
ADMA Biologics
Feb 29, 2024
Maintains: Overweight
Price Target: $6.5 → $8
Current: $6.55
Upside: +22.14%
Amicus Therapeutics
Feb 29, 2024
Reiterates: Overweight
Price Target: $22
Current: $10.28
Upside: +114.01%
Sarepta Therapeutics
Feb 29, 2024
Reiterates: Neutral
Price Target: $128
Current: $128.77
Upside: -0.60%
Lineage Cell Therapeutics
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $1.14
Upside: +426.32%
Capricor Therapeutics
Jan 5, 2024
Initiates: Overweight
Price Target: $8
Current: $5.41
Upside: +47.87%
uniQure
Dec 20, 2023
Reiterates: Overweight
Price Target: $21
Current: $4.53
Upside: +363.58%
Disc Medicine
Dec 20, 2023
Reiterates: Overweight
Price Target: $85
Current: $27.55
Upside: +208.53%
Soleno Therapeutics
Sep 26, 2023
Maintains: Overweight
Price Target: $19 → $35
Current: $37.89
Upside: -7.63%
Outlook Therapeutics
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $8.43
Upside: +137.25%
Alpha Tau Medical
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $2.41
Upside: +856.34%
Mustang Bio
Aug 24, 2023
Reiterates: Overweight
Price Target: $18
Current: $0.32
Upside: +5,594.40%
Ocuphire Pharma
Aug 14, 2023
Reiterates: Overweight
Price Target: $17
Current: $1.61
Upside: +955.90%
DURECT
Aug 10, 2023
Maintains: Overweight
Price Target: $44 → $41
Current: $0.93
Upside: +4,302.45%
X4 Pharmaceuticals
Mar 22, 2023
Maintains: Overweight
Price Target: $3
Current: $1.17
Upside: +157.51%
Galecto
Mar 17, 2023
Initiates: Overweight
Price Target: $16
Current: $0.70
Upside: +2,170.15%
iBio, Inc.
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $1.76
Upside: +4,729.55%
Hepion Pharmaceuticals
Feb 28, 2022
Initiates: Overweight
Price Target: $70
Current: $1.37
Upside: +5,009.49%
Evelo Biosciences
Jun 23, 2021
Initiates: Overweight
Price Target: n/a
Current: $0.05
Upside: -
Chemomab Therapeutics
May 26, 2021
Initiates: Overweight
Price Target: n/a
Current: $0.64
Upside: -
Ocugen
May 7, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.28
Upside: -
Marker Therapeutics
Mar 19, 2021
Initiates: Overweight
Price Target: n/a
Current: $4.29
Upside: -
Evogene
Dec 1, 2020
Initiates: Overweight
Price Target: n/a
Current: $0.63
Upside: -
Galmed Pharmaceuticals
Jan 30, 2020
Assumes: Overweight
Price Target: n/a
Current: $0.39
Upside: -
BiomX
Jan 9, 2020
Initiates: Overweight
Price Target: n/a
Current: $0.35
Upside: -